Blastic plasmacytoid dendritic cell neoplasm

The EU has approved 1 indication of 1 drug in blastic plasmacytoid dendritic cell neoplasm. None of them needs a biomarker result.
Approved indications, Blastic plasmacytoid dendritic cell neoplasm
DrugBiomarker requirementRegimenSettingConditions
No biomarker required1
Tagraxofusp
Elzonris
None
Monotherapy
1L
None
Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Tagraxofusp (Elzonris)
    ELZONRIS is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (see section 5.1).